Hvivo (HVO) RNS Announcements

Add to Alert list
Date Time Source Announcement
11 Oct 2024 07:00 AM
RNS
Long Term Incentive Plan/ PDMR Notification
07 Oct 2024 07:00 AM
RNS
Positive results from RSV human challenge trial
30 Sep 2024 07:00 AM
RNS
Launch of full suite of hLAB standalone services
24 Sep 2024 07:00 AM
RNS
Holding(s) in Company
17 Sep 2024 07:00 AM
RNS
Holding(s) in Company
13 Sep 2024 07:00 AM
RNS
Holding(s) in Company
10 Sep 2024 07:00 AM
RNS
Interim results
05 Sep 2024 07:00 AM
RNS
Holding(s) in Company
20 Aug 2024 07:00 AM
RNS
Notice of results
06 Aug 2024 03:07 PM
RNS
Holding(s) in Company
05 Aug 2024 07:00 AM
RNS
Euronext cancellation
24 Jul 2024 01:55 PM
RNS
Holding(s) in Company
23 Jul 2024 02:48 PM
RNS
Director/PDMR Shareholding
17 Jul 2024 07:01 AM
RNS
Holding(s) in Company
17 Jul 2024 07:00 AM
RNS
Trading update
08 Jul 2024 07:00 AM
RNS
Holding(s) in Company
03 Jul 2024 02:48 PM
RNS
Holding(s) in Company
02 Jul 2024 07:02 AM
RNS
Change of registered address
02 Jul 2024 07:01 AM
RNS
Capital Markets Day & Notice of trading update
02 Jul 2024 07:00 AM
RNS
Influenza 2b field study contract
03 Jun 2024 07:00 AM
RNS
£2.5m contract for Omicron characterisation study
13 May 2024 01:02 PM
RNS
Result of AGM
15 Apr 2024 07:00 AM
RNS
Annual Report & Notice of AGM
09 Apr 2024 07:09 AM
RNS
Final results
27 Mar 2024 07:00 AM
RNS
Notice of Results
22 Mar 2024 03:03 PM
RNS
Holding(s) in Company
14 Mar 2024 07:00 AM
RNS
Holding(s) in Company
15 Feb 2024 07:00 AM
RNS
Long Term Incentive Plan / PDMR Notification
14 Feb 2024 01:14 PM
RNS
Result of Secondary Placing
14 Feb 2024 07:00 AM
RNS
Proposed Secondary Placing of Ordinary Shares
02 Feb 2024 12:44 PM
RNS
Holding(s) in Company
30 Jan 2024 07:00 AM
RNS
Trading update
08 Jan 2024 07:00 AM
RNS
Broker change
02 Jan 2024 07:00 AM
RNS
£6.3m HRV contract signed with biotech client
13 Dec 2023 07:00 AM
RNS
£16.8m RSV contract & Trading ahead of guidance
05 Oct 2023 07:00 AM
RNS
Positive results from flu human challenge study
12 Sep 2023 07:00 AM
RNS
Interim results
01 Sep 2023 07:00 AM
RNS
Exercise of Warrants
29 Aug 2023 07:00 AM
RNS
Plans for a new larger state-of-the-art facility
24 Aug 2023 07:00 AM
RNS
Notice of Results
26 Jul 2023 07:00 AM
RNS
Trading update
25 Jul 2023 07:00 AM
RNS
Flu B challenge model
28 Jun 2023 07:00 AM
RNS
hMPV human challenge model
14 Jun 2023 08:00 AM
RNS
Director dealings
23 May 2023 12:36 PM
RNS
Result of AGM
28 Apr 2023 07:00 AM
RNS
Annual Report and Notice of AGM
26 Apr 2023 07:00 AM
RNS
FDA Breakthrough and Fast Track for US biotech
25 Apr 2023 07:00 AM
RNS
Final results
25 Apr 2023 07:00 AM
RNS
Final results
19 Apr 2023 07:10 AM
RNS
Notice of Results

hVIVO is a contract research organization that conducts human challenge clinical trials for respiratory and infectious disease vaccines and therapeutics:

hVIVO offers services such as challenge trials, assay development, field trial bio-logistics, cell based assays, molecular services, compound efficacy and VRM, and biomarker analysis.

Formerly known as Retroscreen, hVIVO was renamed in 2015 when it went public on the London Stock Exchange.

hVIVO has a portfolio of 11 human challenge models, with more models in development. Their portfolio includes models for influenza, respiratory syncytial virus, human rhinovirus, asthma, COPD, cough, malaria, COVID-19, and hMPV.

hVIVO share price launched at 33p in 2012.

UK 100

Latest directors dealings